![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Attachment Inhibitor Prodrug BMS-663068 in Antiretroviral-Experienced Subjects: Week 96 Analysis
|
|
|
Reported by Jules Levin
CROI 2016 Feb 22-24 Boston
E DeJesus,1 M Martins,2 A Stoehr,3 JA Villanueva,4 N Zakharova,5 DA Stock,6 C Llamoso,6 SR Joshi,6 GJ Hanna,7 M Lataillade6
1. Orlando Immunology Center, Orlando, FL, USA; 2. Instituto Oulton, Cordoba, Argentina; 3. IFI Institute for Interdisciplinary Medicine, Asklepios Klinik St Georg, Hamburg, Germany;4. HIV Unit, Hospital Civil de Guadalajara "Fray Antonio Alcalde", Guadalajara, Mexico; 5. Saint-Petersburg GUZ Center of AIDS, St Petersburg, Russian Federation;6. Bristol-Myers Squibb, Research and Development, Wallingford, CT, USA; 7. Bristol-Myers Squibb, Research and Development, Princeton, NJ, USA
![CROI1](../images/022616/022616-9/CROI1.gif)
![CROI2](../images/022616/022616-9/CROI2.gif)
![CROI3](../images/022616/022616-9/CROI3.gif)
![CROI4](../images/022616/022616-9/CROI4.gif)
![CROI5](../images/022616/022616-9/CROI5.gif)
![CROI6](../images/022616/022616-9/CROI6.gif)
![CROI7](../images/022616/022616-9/CROI7.gif)
![CROI8](../images/022616/022616-9/CROI8.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|